Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
Identifieur interne : 000669 ( Main/Corpus ); précédent : 000668; suivant : 000670Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
Auteurs : Olivier Rascol ; Bruno Dubois ; Alexandre Castro Caldas ; Stephen Senn ; Susanna Del Signore ; Andrew LeesSource :
- Movement Disorders [ 0885-3185 ] ; 2006-12.
English descriptors
- KwdEn :
Abstract
Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21122
Links to Exploration step
ISTEX:4978C7624F02F4B0130A6FACC88D4C85DA47167DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name><affiliation><mods:affiliation>Instituto de Ciënsas da Saùde, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name><affiliation><mods:affiliation>Department of Statistics, University of Glasgow, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4978C7624F02F4B0130A6FACC88D4C85DA47167D</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21122</idno><idno type="url">https://api.istex.fr/document/4978C7624F02F4B0130A6FACC88D4C85DA47167D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000669</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name><affiliation><mods:affiliation>Instituto de Ciënsas da Saùde, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name><affiliation><mods:affiliation>Department of Statistics, University of Glasgow, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12">2006-12</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2110">2110</biblScope><biblScope unit="page" to="2115">2115</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4978C7624F02F4B0130A6FACC88D4C85DA47167D</idno><idno type="DOI">10.1002/mds.21122</idno><idno type="ArticleID">MDS21122</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term><term>Parkinson's disease</term><term>monotherapy</term><term>piribedil</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse, France</json:string></affiliations></json:item><json:item><name>Bruno Dubois MD</name><affiliations><json:string>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Alexandre Castro Caldas MD</name><affiliations><json:string>Instituto de Ciënsas da Saùde, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Stephen Senn MD</name><affiliations><json:string>Department of Statistics, University of Glasgow, Glasgow, United Kingdom</json:string></affiliations></json:item><json:item><name>Susanna Del Signore MD</name><affiliations><json:string>Institut de Recherches Internationales Servier, Courbevoie, France</json:string></affiliations></json:item><json:item><name>Andrew Lees MD</name><affiliations><json:string>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>piribedil</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>L‐dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>monotherapy</value></json:item></subject><articleId><json:string>MDS21122</json:string></articleId><language><json:string>eng</json:string></language><abstract>Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P > 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P > 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P > 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P > 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>6.582</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1671</abstractCharCount><pdfWordCount>3582</pdfWordCount><pdfCharCount>22835</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>265</abstractWordCount></qualityIndicators><title>Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title><genre><json:string>article</json:string></genre><host><volume>21</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>2115</last><first>2110</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.21122</json:string></doi><id>4978C7624F02F4B0130A6FACC88D4C85DA47167D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4978C7624F02F4B0130A6FACC88D4C85DA47167D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4978C7624F02F4B0130A6FACC88D4C85DA47167D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4978C7624F02F4B0130A6FACC88D4C85DA47167D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allée Jules Guesde, 31000 Toulouse, France</p></note><affiliation>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse, France</affiliation></author><author><persName><forename type="first">Bruno</forename><surname>Dubois</surname></persName><roleName type="degree">MD</roleName><affiliation>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Alexandre Castro</forename><surname>Caldas</surname></persName><roleName type="degree">MD</roleName><affiliation>Instituto de Ciënsas da Saùde, Lisbon, Portugal</affiliation></author><author><persName><forename type="first">Stephen</forename><surname>Senn</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Statistics, University of Glasgow, Glasgow, United Kingdom</affiliation></author><author><persName><forename type="first">Susanna</forename><surname>Del Signore</surname></persName><roleName type="degree">MD</roleName><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Lees</surname></persName><roleName type="degree">MD</roleName><affiliation>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12"></date><biblScope unit="volume">21</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2110">2110</biblScope><biblScope unit="page" to="2115">2115</biblScope></imprint></monogr><idno type="istex">4978C7624F02F4B0130A6FACC88D4C85DA47167D</idno><idno type="DOI">10.1002/mds.21122</idno><idno type="ArticleID">MDS21122</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>piribedil</term></item><item><term>L‐dopa</term></item><item><term>Parkinson's disease</term></item><item><term>monotherapy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-04-20">Received</change><change when="2006-06-14">Registration</change><change when="2006-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4978C7624F02F4B0130A6FACC88D4C85DA47167D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v21:12</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2006-12">December 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21122</doi><idGroup><id type="unit" value="MDS21122"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-04-20"></event><event type="manuscriptRevised" date="2006-06-06"></event><event type="manuscriptAccepted" date="2006-06-14"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-09-29"></event><event type="firstOnline" date="2006-09-29"></event><event type="publishedOnlineFinalForm" date="2006-12-19"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2110</numbering><numbering type="pageLast">2115</numbering></numberingGroup><correspondenceTo>Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allée Jules Guesde, 31000 Toulouse, France</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21122.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="28"></count><count type="wordTotal" number="4112"></count></countGroup><titleGroup><title type="main" xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title><title type="short" xml:lang="en">Early Piribedil Monotherapy for PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>rascol@cict.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Bruno</givenNames><familyName>Dubois</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Alexandre Castro</givenNames><familyName>Caldas</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Stephen</givenNames><familyName>Senn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Susanna</givenNames><familyName>Del Signore</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="PT" type="organization"><unparsedAffiliation>Instituto de Ciënsas da Saùde, Lisbon, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>Department of Statistics, University of Glasgow, Glasgow, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Institut de Recherches Internationales Servier, Courbevoie, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="GB" type="organization"><unparsedAffiliation>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">piribedil</keyword><keyword xml:id="kwd2"><sc>L</sc>‐dopa</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">monotherapy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Piribedil is a D<sub>2</sub> dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with <sc>L</sc>‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. <sc>L</sc>‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; <i>P</i> < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; <i>P</i> < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; <i>P</i> < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; <i>P</i> < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Early Piribedil Monotherapy for PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title></titleInfo><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse, France</affiliation><description>Correspondence: Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allée Jules Guesde, 31000 Toulouse, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexandre Castro</namePart><namePart type="family">Caldas</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Instituto de Ciënsas da Saùde, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephen</namePart><namePart type="family">Senn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Statistics, University of Glasgow, Glasgow, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Susanna</namePart><namePart type="family">Del Signore</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-12</dateIssued><dateCaptured encoding="w3cdtf">2006-04-20</dateCaptured><dateValid encoding="w3cdtf">2006-06-14</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">3</extent><extent unit="references">28</extent><extent unit="words">4112</extent></physicalDescription><abstract lang="en">Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>piribedil</topic><topic>L‐dopa</topic><topic>Parkinson's disease</topic><topic>monotherapy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>2110</start><end>2115</end><total>6</total></extent></part></relatedItem><identifier type="istex">4978C7624F02F4B0130A6FACC88D4C85DA47167D</identifier><identifier type="DOI">10.1002/mds.21122</identifier><identifier type="ArticleID">MDS21122</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000669 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000669 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:4978C7624F02F4B0130A6FACC88D4C85DA47167D
|texte= Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
}}
| This area was generated with Dilib version V0.6.23. |  |